14-Sep-2022 - High-Tech Gründerfonds Management GmbH

C-mo Medical Solutions raises €4.1 million aiming to transform cough monitoring

C-mo Medical Solutions is an award-winning start-up that is unravelling the potential of assessing cough towards improved diagnosis, treatment courses and disease management. The company has now raised 4.1€Mn in a seed round led by Boehringer Ingelheim Venture Fund. This investment will allow the company to bring its innovative cough-monitoring technology to the market.

The round was led by Boehringer Ingelheim Venture Fund with participation of Portugal Ventures and High-Tech Gründerfonds. This marks the first investment round of the company that was previously awarded by the European Institute of Innovation & Technology for Health and by the Portuguese Innovation Agency.

C-mo Medical Solutions is working to solve the pressing need to better assess chronic cough. Diogo Tecelão, co-founder and CEO of the company, explains: “Chronic cough is a highly prevalent symptom, being responsible for up to 40% of the pulmonologists’ workload. At the same time, cough is a symptom that hides extremely valuable information about the patient’s health, thus bringing tremendous clinical value. The European Respiratory Society stated in 2019 that there is an urgent need for suitable cough monitoring technologies – developing a solution has been our mission since!”

The company is unravelling the clinical value of cough through C-mo’s innovative product suite. C-mo’s unique technology analyses the subtle characteristics of the patient’s cough and translates them into actionable insights.

"C-mo is the first and only solution that can monitor the patient’s cough seamlessly, over long periods of time, and while protecting the patient’s privacy. It is also the first tool providing a complete and holistic assessment of the patient’s cough traits, thus enabling its application in several key use-cases", Diogo Tecelão, co-founder and CEO of C-mo Medical Solutions.

Overall, C-mo answers an urgent medical need and represents a powerful solution to speed-up diagnosis, optimise treatment courses, improve disease management, and support pharmaceutical research.

"We are excited about the novel C-mo technology in analysing cough and think that it will provide great value by allowing for a more specific diagnosis, and by empowering patients to better understand and manage their disease", Dr. Alexander Ehlgen, Investment Manager at Boehringer Ingelheim Venture Fund.

"We’re proud to be investing in C-mo Medical Solutions. This round will enable the company to continue developing their product and meeting the medical needs related to the personalised management of chronic cough and doctor-patient interactions, alongside internationalisation to the European and US markets", Teresa Fiúza, Executive Vice President of Portugal Ventures.

"C-mo is addressing an unmet clinical need. Its solution has the potential to significantly improve how cough-related diseases are diagnosed, managed and treated. This seed round will enable the company to obtain key clinical evidence and to further develop its platform. We look forward to supporting the team on its journey", Niels Sharman, Investment Manager at High-Tech Gründerfonds.

"We are excited to bring onboard strategic and valuable investors that share our vision. We believe C-mo will cause a paradigm shift on how cough is addressed, respiratory diseases are monitored, and new drugs are launched to the market", Diogo Tecelão, co-founder and CEO of C-mo Medical Solutions.

Facts, background information, dossiers
  • cough
  • diagnosis
  • seed financing
More about High-Tech Gründerfonds Management